NIAID's Comprehensive Support Mechanisms for Antibiotic Development.

ACS Infectious Diseases
Erin M Zeituni, Erica L Raterman

Abstract

The National Institute of Allergy and Infectious Diseases (NIAID) recognizes the continuing threat of antimicrobial resistance and the need to develop new therapeutics and strategies to combat multidrug resistant organisms. NIAID leverages multiple mechanisms to help support antibiotic developers struggling in the "valley of death" of preclinical antibiotic development. The Division of Microbiology and Infectious Diseases' (DMID) preclinical services are a comprehensive set of services to facilitate efforts to develop vaccines, diagnostics, and therapeutics for a broad array of bacterial, viral, fungal, and parasitic pathogens. These services are available to investigators worldwide at no charge.

References

Mar 7, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A S Fauci
Jun 4, 2004·Seminars in Pediatric Infectious Diseases·B Lee Ligon
Apr 3, 2008·The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Médicale·Julian Davies
Apr 19, 2008·The Journal of Infectious Diseases·N Kent PetersAnthony S Fauci
Sep 20, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gerald B Pier
Sep 2, 2010·Microbiology and Molecular Biology Reviews : MMBR·Julian Davies, Dorothy Davies
Jul 16, 2013·Infectious Diseases of Poverty·Brad Spellberg, Bonnie Taylor-Blake
Feb 7, 2016·The Journal of Antimicrobial Chemotherapy·Kate Gould

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.